[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Incyte Corp (INCY)

Incyte Corp (INCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,725,200
  • Shares Outstanding, K 199,782
  • Annual Sales, $ 5,141 M
  • Annual Income, $ 1,287 M
  • EBIT $ 1,611 M
  • EBITDA $ 1,704 M
  • 60-Month Beta 0.79
  • Price/Sales 4.18
  • Price/Cash Flow 17.55
  • Price/Book 3.85

Options Overview Details

View History
  • Implied Volatility 35.19% (+4.09%)
  • Historical Volatility 41.69%
  • IV Percentile 34%
  • IV Rank 25.81%
  • IV High 64.77% on 10/31/25
  • IV Low 24.90% on 08/08/25
  • Expected Move (DTE 20) 5.78 (5.08%)
  • Put/Call Vol Ratio 0.09
  • Today's Volume 2,810
  • Volume Avg (30-Day) 851
  • Put/Call OI Ratio 0.55
  • Today's Open Interest 11,039
  • Open Int (30-Day) 15,744
  • Expected Range 107.97 to 119.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.56
  • Number of Estimates 8
  • High Estimate $1.73
  • Low Estimate $1.25
  • Prior Year $1.31
  • Growth Rate Est. (year over year) +19.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
92.18 +23.40%
on 06/02/26
115.56 -1.57%
on 06/26/26
+16.65 (+17.15%)
since 05/26/26
3-Month
90.08 +26.27%
on 03/30/26
115.56 -1.57%
on 06/26/26
+21.49 (+23.29%)
since 03/26/26
52-Week
66.83 +70.21%
on 07/01/25
115.56 -1.57%
on 06/26/26
+42.94 (+60.64%)
since 06/26/25

Most Recent Stories

More News
Stock Indexes Finish Lower as Chipmakers Sell Off

The S&P 500 Index ($SPX ) (SPY ) on Friday closed down -0.05%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.09%. September...

SNDK : 2,090.71 (-10.46%)
STX : 899.90 (-12.24%)
WDC : 586.45 (-13.17%)
SPY : 728.99 (-0.72%)
ADSK : 196.26 (+3.44%)
MU : 1,132.33 (-6.69%)
QMCO : 11.65 (-9.90%)
NUTX : 166.40 (+11.60%)
QQQ : 706.52 (-1.38%)
FTNT : 151.35 (+0.95%)
NOW : 98.34 (+9.85%)
ADBE : 202.73 (+4.82%)
Stock Indexes Slip as Chipmakers Retreat

The S&P 500 Index ($SPX ) (SPY ) today is down -0.07%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.75%. September E-mini S&P futures...

AMAT : 626.84 (-6.16%)
AVGO : 365.02 (-3.67%)
SNDK : 2,090.71 (-10.46%)
INTU : 267.72 (+4.96%)
DDOG : 239.77 (+8.52%)
TXN : 285.42 (-8.46%)
$IUXX : 29,118.24 (-1.09%)
ASML : 1,794.62 (-2.53%)
ZNU26 : 110-085s (+0.16%)
MSFT : 372.97 (+5.71%)
ESU26 : 7,401.75s (-0.29%)
STX : 899.90 (-12.24%)
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis

If approved, Opzelura ® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD)...

INCY : 113.75 (+5.78%)
Stocks Mostly Lower on Weakness in Megacap Tech and Software Stocks

The S&P 500 Index ($SPX ) (SPY ) on Monday closed down -0.37%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.29%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.19%. September...

GOOGL : 337.39 (-1.84%)
AAPL : 283.78 (+3.14%)
SNDK : 2,090.71 (-10.46%)
ADI : 386.91 (-7.42%)
TSLA : 379.71 (+1.22%)
STX : 899.90 (-12.24%)
AMD : 521.58 (-2.06%)
DFTX : 44.95 (+0.36%)
SPY : 728.99 (-0.72%)
META : 550.25 (+1.36%)
NOC : 500.03 (+0.14%)
FRVO : 32.48 (+2.27%)
Incyte Stock: Is INCY Outperforming the Healthcare Sector?

Incyte has rallied the healthcare sector over the past year, and analysts remain moderately optimistic about its prospects.

XLV : 160.34 (+3.03%)
INCY : 113.75 (+5.78%)
INSM : 103.38 (-1.04%)
2 Growth Stocks to Add to Your Roster and 1 We Avoid

2 Growth Stocks to Add to Your Roster and 1 We Avoid

AVAV : 137.95 (+0.93%)
INCY : 113.75 (+5.78%)
AJG : 226.01 (+3.74%)
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi ® (tafasitamab) in combination with lenalidomide for the...

INCY : 113.75 (+5.78%)
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva

- Cohort 1 results presented at ENDO 2026 demonstrate meaningful reductions in total heterotopic ossification (HO) lesion volume, new HO lesions and flare activity in adolescents and adults with...

MIRM : 123.77 (+5.53%)
INCY : 113.75 (+5.78%)
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination...

INCY : 113.75 (+5.78%)
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival

- frontMIND study evaluating tafasitamab (Monjuvi ® /Minjuvi ® ) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL)...

INCY : 113.75 (+5.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2...

See More

Key Turning Points

3rd Resistance Point 122.47
2nd Resistance Point 119.01
1st Resistance Point 116.38
Last Price 113.75
1st Support Level 110.30
2nd Support Level 106.84
3rd Support Level 104.21

See More

52-Week High 115.56
Last Price 113.75
Fibonacci 61.8% 96.95
Fibonacci 50% 91.19
Fibonacci 38.2% 85.44
52-Week Low 66.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.